AEON
AEON Biopharma, Inc.
Price Chart
Latest Quote
$1.16
Current Price| Previous Close | $1.16 |
| Open | $1.16 |
| Day High | $1.19 |
| Day Low | $1.13 |
| Volume | 142,952 |
Stock Information
| Shares Outstanding | 24.02M |
| Total Debt | $18.25M |
| Cash Equivalents | $5.93M |
| Net Income | $-3K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $27.87M |
| P/E Ratio | 0.39 |
| EPS (TTM) | $2.98 |
| Exchange | ASE |
đ Custom Metrics & Score
Score: 5/42| Debt to Equity | -0.45 |
| Debt to Earnings | 0.31 |
| Current Ratio | 0.11 |
| Quick Ratio | 0.00 |
| Return on Equity | -147.03% |
| Avg FCF Growth | -9.69% |
| FCF Yield | -72.81% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.16 | 142,952 |
| 2026-01-30 | $1.16 | 92,900 |
| 2026-01-29 | $1.19 | 50,500 |
| 2026-01-28 | $1.18 | 86,000 |
| 2026-01-27 | $1.20 | 89,700 |
| 2026-01-26 | $1.19 | 130,100 |
| 2026-01-23 | $1.11 | 163,300 |
| 2026-01-22 | $1.17 | 1,852,900 |
| 2026-01-21 | $1.36 | 492,500 |
| 2026-01-20 | $1.20 | 514,200 |
| 2026-01-16 | $1.14 | 63,700 |
| 2026-01-15 | $1.15 | 212,000 |
| 2026-01-14 | $1.11 | 237,600 |
| 2026-01-13 | $1.09 | 200,000 |
| 2026-01-12 | $1.10 | 139,500 |
| 2026-01-09 | $1.08 | 87,500 |
| 2026-01-08 | $1.09 | 214,500 |
| 2026-01-07 | $1.18 | 168,900 |
| 2026-01-06 | $1.24 | 174,100 |
| 2026-01-05 | $1.13 | 415,800 |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
đ° Latest News
An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% Undervalued
Simply Wall St. âĸ 2026-01-14T07:37:23Z
Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year
Simply Wall St. âĸ 2025-12-15T02:14:04Z
The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't Growing
Simply Wall St. âĸ 2025-10-22T06:14:57Z
Aeon Co. (M) Bhd.'s (KLSE:AEON) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Simply Wall St. âĸ 2025-09-29T00:02:01Z
Aeon Co. (M) Bhd.'s (KLSE:AEON) largest shareholders are public companies with 52% ownership, institutions own 33%
Simply Wall St. âĸ 2025-09-12T03:41:25Z
Aeon (M) Bhd Second Quarter 2025 Earnings: EPS: RM0.009 (vs RM0.02 in 2Q 2024)
Simply Wall St. âĸ 2025-08-26T22:11:29Z
Are Investors Undervaluing Aeon Co. (M) Bhd. (KLSE:AEON) By 39%?
Simply Wall St. âĸ 2025-08-07T06:07:33Z
Those who invested in Aeon (M) Bhd (KLSE:AEON) five years ago are up 66%
Simply Wall St. âĸ 2025-07-07T07:17:02Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | - | $0 | $0 |
| Operating Revenue | $0 | - | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $27,824,000 | - | $48,429,000 | $36,881,000 |
| Other Income Expense | $69,829,000 | - | $-4,127,000 | $-18,756,000 |
| Other Non Operating Income Expenses | $95,000 | - | $289,000 | $9,415,000 |
| Operating Expense | $27,824,000 | - | $48,429,000 | $36,881,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Normalized Income | $-27,729,000 | - | $-48,140,000 | $-27,466,000 |
| Net Income From Continuing And Discontinued Operation | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Total Operating Income As Reported | $72,985,000 | - | $-48,429,000 | $-65,847,000 |
| Net Income Common Stockholders | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Net Income | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Net Income Including Noncontrolling Interests | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Net Income Continuous Operations | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Pretax Income | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Special Income Charges | $100,809,000 | - | $0 | $-28,966,000 |
| Operating Income | $-27,824,000 | - | $-48,429,000 | $-36,881,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $72.93 | - | $-172.03 | $-182.12 |
| Basic EPS | $77.74 | - | $-172.03 | $-182.12 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | - | $0 | $0 |
| Tax Rate For Calcs | $0 | - | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-97,461,000 | - | $-43,945,000 | $-8,707,000 |
| Total Unusual Items | $69,734,000 | - | $-4,416,000 | $-28,171,000 |
| Total Unusual Items Excluding Goodwill | $69,734,000 | - | $-4,416,000 | $-28,171,000 |
| Reconciled Depreciation | $97,000 | - | $68,000 | $3,000 |
| EBITDA (Bullshit earnings) | $-27,727,000 | - | $-48,361,000 | $-36,878,000 |
| EBIT | $-27,824,000 | - | $-48,429,000 | $-36,881,000 |
| Diluted Average Shares | $575,945 | $516,105 | $305,501 | $305,501 |
| Basic Average Shares | $540,359 | $516,105 | $305,501 | $305,501 |
| Diluted NI Availto Com Stockholders | $42,005,000 | - | $-52,556,000 | $-55,637,000 |
| Tax Provision | $0 | - | $0 | $0 |
| Restructuring And Mergern Acquisition | $-100,809,000 | - | $0 | - |
| Gain On Sale Of Security | $-31,075,000 | - | $-4,416,000 | $795,000 |
| Research And Development | $14,181,000 | - | $34,754,000 | $25,728,000 |
| Selling General And Administration | $13,643,000 | - | $13,675,000 | $11,153,000 |
| Other Special Charges | - | - | - | $28,966,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-28,569,000 | $-153,044,000 | $-287,500,000 | $-234,944,000 |
| Total Assets | $3,142,000 | $6,845,000 | $10,778,000 | $6,436,000 |
| Total Non Current Assets | $1,552,000 | $623,000 | $940,000 | $1,282,000 |
| Other Non Current Assets | $29,000 | $29,000 | $34,000 | $360,000 |
| Current Assets | $1,590,000 | $6,222,000 | $9,838,000 | $5,154,000 |
| Other Current Assets | $1,577,000 | $1,064,000 | $92,000 | $26,000 |
| Cash Cash Equivalents And Short Term Investments | $13,000 | $5,158,000 | $9,746,000 | $5,128,000 |
| Cash And Cash Equivalents | $13,000 | $5,158,000 | $9,746,000 | $5,128,000 |
| Cash Financial | - | $5,158,000 | $9,746,000 | $5,128,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $11,676,000 | - | $121,546,000 | $81,237,000 |
| Total Debt | $12,955,000 | $278,000 | $131,791,000 | $86,889,000 |
| Long Term Debt And Capital Lease Obligation | $12,834,000 | $0 | $60,668,000 | $71,286,000 |
| Long Term Debt | $11,689,000 | - | $60,426,000 | $70,762,000 |
| Current Debt And Capital Lease Obligation | $121,000 | $278,000 | $71,123,000 | $15,603,000 |
| Current Debt | - | - | $70,866,000 | $15,603,000 |
| Other Current Borrowings | - | - | $70,866,000 | $15,603,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $31,711,000 | $159,889,000 | $281,191,000 | $230,260,000 |
| Total Non Current Liabilities Net Minority Interest | $17,562,000 | $146,840,000 | $198,617,000 | $209,456,000 |
| Other Non Current Liabilities | $3,541,000 | $104,350,000 | - | $221,000 |
| Derivative Product Liabilities | $1,187,000 | $42,490,000 | $0 | - |
| Current Liabilities | $14,149,000 | $13,049,000 | $82,574,000 | $20,804,000 |
| Payables And Accrued Expenses | $12,960,000 | $11,828,000 | $10,339,000 | $4,135,000 |
| Payables | $6,479,000 | $3,957,000 | $7,805,000 | $1,192,000 |
| Total Tax Payable | $569,000 | $569,000 | $0 | - |
| Accounts Payable | $5,910,000 | $3,388,000 | $7,805,000 | $1,192,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-28,569,000 | $-153,044,000 | $-287,500,000 | $-234,944,000 |
| Total Equity Gross Minority Interest | $-28,569,000 | $-153,044,000 | $-270,413,000 | $-223,824,000 |
| Stockholders Equity | $-28,569,000 | $-153,044,000 | $-287,500,000 | $-234,944,000 |
| Retained Earnings | $-431,597,000 | $-473,602,000 | $-474,839,000 | $-422,283,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $137,949,000 | $137,949,000 |
| Other Equity Interest | - | $-60,710,000 | - | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $555,511 | $516,105 | $380,982 | $380,982 |
| Share Issued | $555,511 | $516,105 | $380,982 | $380,982 |
| Tangible Book Value | $-28,569,000 | $-153,044,000 | $-287,500,000 | $-234,944,000 |
| Invested Capital | $-16,880,000 | $-153,044,000 | $-156,208,000 | $-148,579,000 |
| Working Capital | $-12,559,000 | $-6,827,000 | $-72,736,000 | $-15,650,000 |
| Capital Lease Obligations | $1,266,000 | $278,000 | $499,000 | $524,000 |
| Total Capitalization | $-16,880,000 | $-153,044,000 | $-227,074,000 | $-164,182,000 |
| Minority Interest | $0 | $0 | $17,087,000 | $11,120,000 |
| Treasury Stock | $0 | $0 | $23,000 | $23,000 |
| Additional Paid In Capital | $403,024,000 | $381,264,000 | $187,348,000 | $187,348,000 |
| Capital Stock | $4,000 | $4,000 | $14,000 | $14,000 |
| Common Stock | $4,000 | $4,000 | $14,000 | $14,000 |
| Long Term Capital Lease Obligation | $1,145,000 | $0 | $242,000 | $524,000 |
| Current Capital Lease Obligation | $121,000 | $278,000 | $257,000 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $1,068,000 | $943,000 | $1,112,000 | $1,066,000 |
| Current Accrued Expenses | $6,481,000 | $7,871,000 | $2,534,000 | $2,943,000 |
| Net PPE | $1,523,000 | $594,000 | $906,000 | $922,000 |
| Accumulated Depreciation | $-267,000 | $-170,000 | $-71,000 | $-3,000 |
| Gross PPE | $1,790,000 | $764,000 | $977,000 | $925,000 |
| Leases | $66,000 | $66,000 | $66,000 | $66,000 |
| Other Properties | $237,000 | $237,000 | $237,000 | $729,000 |
| Machinery Furniture Equipment | $199,000 | $199,000 | $199,000 | $130,000 |
| Buildings And Improvements | $1,288,000 | $262,000 | $475,000 | $729,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Free Cash Flow | $-20,292,000 | $-35,890,000 | $-28,603,000 |
Operating Activities
| Metric | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-20,292,000 | $-35,584,000 | $-28,433,000 |
| Cash Flow From Continuing Operating Activities | $-20,292,000 | $-35,584,000 | $-28,433,000 |
| Operating Gains Losses | $34,386,000 | - | - |
Investing Activities
| Metric | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Investing Cash Flow | $0 | $-306,000 | $-170,000 |
| Capital Expenditure | - | $-306,000 | $-170,000 |
| Cash Flow From Continuing Investing Activities | - | $-306,000 | $-170,000 |
Financing Activities
| Metric | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $147,000 | - | - |
| Financing Cash Flow | $15,147,000 | $40,508,000 | $13,563,000 |
| Cash Flow From Continuing Financing Activities | $15,147,000 | $40,508,000 | $13,563,000 |
| Net Common Stock Issuance | $147,000 | - | - |
| Common Stock Issuance | $147,000 | - | - |
| Net Other Financing Charges | - | - | $-1,437,000 |
Other
| Metric | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Issuance Of Debt | $15,000,000 | $44,500,000 | $15,000,000 |
| End Cash Position | $13,000 | $9,746,000 | $5,128,000 |
| Beginning Cash Position | $5,158,000 | $5,128,000 | $20,168,000 |
| Changes In Cash | $-5,145,000 | $4,618,000 | $-15,040,000 |
| Net Issuance Payments Of Debt | $15,000,000 | $40,508,000 | $15,000,000 |
| Net Long Term Debt Issuance | $15,000,000 | $40,508,000 | $15,000,000 |
| Long Term Debt Issuance | $15,000,000 | $44,500,000 | $15,000,000 |
| Change In Working Capital | $706,000 | $6,268,000 | $1,416,000 |
| Change In Other Working Capital | $120,000 | $-174,000 | $-26,000 |
| Change In Payables And Accrued Expense | $1,099,000 | $6,508,000 | $1,260,000 |
| Change In Accrued Expense | $-1,423,000 | $-105,000 | $2,158,000 |
| Change In Payable | $2,522,000 | $6,613,000 | $-898,000 |
| Change In Account Payable | $2,522,000 | $6,613,000 | $-898,000 |
| Change In Prepaid Assets | $-513,000 | $-66,000 | $182,000 |
| Other Non Cash Items | $-103,736,000 | $4,413,000 | $18,587,000 |
| Stock Based Compensation | $6,250,000 | $5,892,000 | $5,220,000 |
| Depreciation Amortization Depletion | $97,000 | $68,000 | $3,000 |
| Depreciation And Amortization | $97,000 | $68,000 | $3,000 |
| Depreciation | $97,000 | $68,000 | $3,000 |
| Gain Loss On Investment Securities | $34,386,000 | - | - |
| Net Income From Continuing Operations | $42,005,000 | $-52,556,000 | $-55,637,000 |
| Repayment Of Debt | - | $-3,992,000 | $0 |
| Long Term Debt Payments | - | $-3,992,000 | $0 |
| Net PPE Purchase And Sale | - | $-306,000 | $-170,000 |
| Purchase Of PPE | - | $-306,000 | $-170,000 |
| Unrealized Gain Loss On Investment Securities | - | $4,416,000 | $-795,000 |
| Asset Impairment Charge | - | $331,000 | $1,978,000 |